PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
H.R. 3167, Playing Fair on Trade and Innovation Act: Provisions related to intellectual property Korea Free Trade Agreement: Implementation issues related to intellectual property, market access and public health Trans-Pacific Partnership (TPP): Provisions related to intellectual property, market access and public health issues Mexico and Canada IP and market access issuesTurkey Market Access Issues India innovation, IP and market access issues Transatlantic Trade and Investment Partnership (TTIP): Market access, intellectual property, regulatory and other issues The Agriculture Reform, Food and Jobs Act of 2013/H.R. 1947, Federal Agriculture Reform and Risk Management Act of 2013: Issues related to World Trade Organization (WTO) Brazil Cotton dispute Issues related to Special 301 and National Trade Estimate (NTE) submissions including intellectual property and market access issues International market access and intellectual property issues Biopharmaceutical innovation policy issues Trade Promotion Authority issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN J CASTELLANI | — |
| CHESTER (CHIP) DAVIS | — |
| LEO FARBER | — |
| LEA FISHER | — |
| JEFFREY FRANCER | — |
| SASCHA HAVERFIELD-GROSS | — |
| DAVID KORN | — |
| COLLEEN MALONEY | — |
| JENNIFER ROMANS | — |
| NICK SHIPLEY | — |
| JAMES M SPEARS | — |
| MATTHEW L SULKALA | — |
Copyright/Patent/Trademark CPT
H.R. 22, Foreign Counterfeit Merchandise Prevention Act: Provisions related to counterfeiting H.R. 845, Saving High-Tech Innovators from Egregious Legal Disputes Act of 2013 (the SHIELD Act): Provisions related to patent litigation H.R. 2024, End Anonymous Patents Act: Patent owner information provisionsH.R. 2582, PATENT Jobs Act: Provisions related to patent user fees H.R. 2605, Manufacturing Innovation in America Act of 2013: Provisions related to patent tax boxes H.R. 2639, Patent Litigation and Innovation Act: Patent litigation proposals H.R. 2766, STOP Act: Provisions related to business method patents H.R. 2985, Combination Drug Development Incentive Act of 2013: Provisions related to exclusivity for combination drugs H.R. 3116, MODDERN Cures Act of 2013: Provisions related to diagnostics and exclusivity H.R. 3309, Innovation Act: Provisions related to patent litigation reform H.R. 3349, Innovation Protection Act: PTO Fee Diversion H.R. 3540, Demand Letter Transparency Act: Provisions related to patent demand letters H.R. 3709, Protecting Consumer Access to Generic Drugs: Provisions related to patent settlements S. 214, Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 504, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 626, Prize Fund for HIV/AIDS Act: Medical prize provisions S. 627, Medical Innovation Prize Fund Act: Medical prize provisions S. 712, Patents for Humanity Program Improvement Act of 2013: Transferability of PTO vouchers provisions S. 866, Patent Quality Improvement Act of 2013: Business methods patents provisions S. 1013, Patent Abuse Reduction Act of 2013: Patent litigation provisions S. 1612, Patent Litigation Integrity Act: Patent litigation provisions including bonding S. 1720, Patent Transparency and Improvements Act of 2013: Provisions related to patent litigation and other reforms Biopharmaceutical innovation policy issues Biologics data protection issues Draft legislation on trade secret issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN J CASTELLANI | — |
| CHESTER (CHIP) DAVIS | — |
| LEO FARBER | — |
| LEA FISHER | — |
| PETER FOTOS | — |
| VALERIE HARDIN JEWETT | — |
| DAVID KORN | — |
| COLLEEN MALONEY | — |
| CARA MOON | — |
| JENNIFER ROMANS | — |
| JAMES M SPEARS | — |
| MATTHEW L SULKALA | — |
Health Issues HCR
H.R. 2674, 340B Program Improvement Act: Provisions related to 340B Drug Pricing Program (112th Congress) H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013: Provisions related to supply chain security H.R. 2090, Patient Choice Act of 2013: To permit provisional approval of fast track productsH.R. 3204, Drug Quality and Security Act: Provisions related to pharmacy compounding and supply chain H.R. 6584, Verifying Authority and Legality In Drug Compounding Act: Provisions related to drug compounding (112th Congress) H.R. 3742, Antibiotic Development to Advance Patient Treatment Act S. 264, Excellence in Mental Health Act: Sets forth criteria for the certification of federally-qualified community behavioral health centers S. 1699, Prescription Drug Cost Reduction Act: Provisions related to 340B Drug Pricing Program (112th Congress) S. 3187, Food and Drug Administration Safety and Innovation Act: Provisions related to user fee reauthorization and FDA reform (112th Congress) S. 957, Drug Supply Chain Security Act: Provisions related to supply chain security S. 959, Pharmaceutical Compounding Quality and Accountability Act: Provisions related to pharmaceutical compounding S. 1723, No ObamaCare Kickbacks Act of 2013: Provisions related to application of the anti-kickback statute to qualified health plans S. 2295, Patient Safety and Generic Labeling Improvement Act: Provisions relating to drug safety labeling (112th Congress) Implementation issues related to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including PPACA; Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation rulemaking Comparative effectiveness policy issues Academic detailing policy issues Drug abuse policy issues General HHS and FDA related advocacy Biopharmaceutical innovation policy issues Prescription drug abuse policy issues FDA accelerated approval policy issues Unapproved use policy issues 340B Drug Pricing Program policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| MAYA BERMINGHAM | — |
| RANDY BURKHOLDER | — |
| JOHN J CASTELLANI | — |
| CHESTER (CHIP) DAVIS | — |
| LEO FARBER | — |
| LEA FISHER | — |
| PETER FOTOS | — |
| JEFFREY FRANCER | — |
| SASCHA HAVERFIELD-GROSS | — |
| VALERIE HARDIN JEWETT | — |
| COLLEEN MALONEY | — |
| CARA MOON | — |
| ANNE PRITCHETT | — |
| LORI REILLY | — |
| JENNIFER ROMANS | — |
| NICK SHIPLEY | — |
| JAMES M SPEARS | — |
| MATTHEW L SULKALA | — |
Medicare/Medicaid MMM
H.R. 351, Protecting Seniors' Access to Medicare Act of 2013: Provisions related to the Independent Payment Advisory Board H.R. 460, Patients' Access to Treatments Act of 2013: Provisions related to capping specialty tier drugs and no cost-sharing above the non-preferred brand tier H.R. 928, Medicare Prescription Drug Savings and Choice Act of 2013: Provisions related to Part D issuesH.R. 1588, Medicare Drug Savings Act of 2013: Provisions related to Part D issues H.R. 2810, Medicare Patient Access and Quality Improvement Act: Provisions related to Sustainable Growth Rate (SGR) reform H.R. 2827, To amend title XVIII of the Social Security Act to allow for fair application of the exceptions process for drugs in tiers in formularies in prescription drug plans under Medicare part D: Provisions related to Medicare Part D Drug Tier Formularies H.R. 2925, Strengthening Medicare Anti-Fraud Measures Act of 2013: Provisions related to fraud and abuse H.R. 3392, Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013: Provisions related to lock-in programs H.R. 3796, Comprehensive Care Payment Innovation Act: Provisions related to alternative payment models S. 117, Medicare Prescription Drug Price Negotiation Act of 2013: Provisions related to Part D issues S. 351, Protecting Seniors Access to Medicare Act of 2013: Provisions related to Independent Payment Advisory Board S. 408, Medicare Prescription Drug Savings and Choice Act of 2013: Provision related to Part D issues S. 740, Medicare Drug Savings Act of 2013: Provisions related to Part D issues Deficit reduction policy issues S. 882, Stop Trafficking of Pills (STOP) Act: Provisions related to lock-in programs (112th Congress) S. 1365, Part D Beneficiary Appeals Fairness Act: Provisions related to the specialty tier in Part D S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013: Provisions related to reforming Medicare physician payments Medicare Prescription Drug Diversion and Abuse Prevention Act: Provisions related to diversion and abuse (no bill number) Proposals to increase co-payments for Part D beneficiaries receiving the low-income subsidy Medicaid Program, Covered Outpatient Drugs rulemaking Medicare sustainable growth rate policy issues Implementation issues relating to the Physician Payment Sunshine Act, including Medicare, Medicaid, Childrens Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Investment Interests rulemaking
| Lobbyist | Covered position, as disclosed |
|---|---|
| MAYA BERMINGHAM | — |
| RANDY BURKHOLDER | — |
| JOHN J CASTELLANI | — |
| CHESTER (CHIP) DAVIS | — |
| LEA FISHER | — |
| VALERIE HARDIN JEWETT | — |
| COLLEEN MALONEY | — |
| CARA MOON | — |
| ANNE PRITCHETT | — |
| LORI REILLY | — |
| JENNIFER ROMANS | — |
| NICK SHIPLEY | — |
| JAMES M SPEARS | — |
| MATTHEW L SULKALA | — |
Budget/Appropriations BUD
H.R. 2216, Military Construction and Veterans Affairs, and Related Agencies Appropriations Act, 2014: Provisions related to Veterans Affairs Administration regulation and funding, VA health benefits H.R. 2217, Department of Homeland Security Appropriations Act, 2014: Provisions related to Customs and Border Control Agency funding, drug importsH.R. 2397, Department of Defense Appropriations Act, 2014: Provisions related to bio-defense H.R. 2410, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2014: Provisions related to FDA regulation and funding, sequestration, drug importation H.R. 2725, Food and Drug Administration Safety Over Sequestration Act of 2013: Provisions related to FDA user fees H.R. 3547, Consolidated Appropriations Act: Provisions in the appropriations bills identified above H.J. Res. 59, FY14 Continuing Resolution Issues related to implementation of The Budget Control Act of 2011: Public Law No. 112-25: Provisions related to sequestration
| Lobbyist | Covered position, as disclosed |
|---|---|
| MAYA BERMINGHAM | — |
| RANDY BURKHOLDER | — |
| JOHN J CASTELLANI | — |
| CHESTER (CHIP) DAVIS | — |
| LEA FISHER | — |
| PETER FOTOS | — |
| JEFFREY FRANCER | — |
| SASCHA HAVERFIELD-GROSS | — |
| VALERIE HARDIN JEWETT | — |
| DAVID KORN | — |
| COLLEEN MALONEY | — |
| CARA MOON | — |
| ANNE PRITCHETT | — |
| LORI REILLY | — |
| JENNIFER ROMANS | — |
| NICK SHIPLEY | — |
| JAMES M SPEARS | — |
| MATTHEW L SULKALA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.